Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095809 | 0.92 | RAB9A (0.66) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL3607557 | 0.83 | HRH3 (0.54) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL3601430 | 0.82 | OPRK1 (0.50) | — | |
| SCHEMBL18555777 | 0.80 | RAB9A (0.64) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL3608747 | 0.80 | SCD (0.67) | RAB9ANPC1KMT2AHRH3 | |
| SCHEMBL3895677 | 0.78 | RAB9A (0.72) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL25141661 | 0.78 | NPC1 (0.62) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL13059656 | 0.77 | RAB9A (0.60) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL7326778 | 0.77 | RAB9A (0.71) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL12734207 | 0.77 | HRH3 (0.57) | RAB9ANPC1KMT2AHRH3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RAB9A 1922/4885NPC1 264/4885KMT2A 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.